Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
2 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
3 Alcoholic liver disease 💬
 1件: C5 💬 D11838 💬 Vilobelimab 3件: 43, 44, 269 💬
4 Alcoholic liver disease 💬
 1件: C5AR1 💬 D11093 💬 Avacopan 3件: 43, 44, 222 💬
5 Allograft rejection 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
6 Allograft rejection 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
7 Allograft rejection 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
8 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
9 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
10 Asthma 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
11 Asthma 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
12 Autoimmune thyroid disease 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
13 Autoimmune thyroid disease 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
14 Autoimmune thyroid disease 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
15 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
16 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
17 Cell adhesion molecules 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
18 cGMP-PKG signaling pathway 💬
 1件: OPRD1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
19 cGMP-PKG signaling pathway 💬
 1件: OPRD1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
20 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
21 Chemokine signaling pathway 💬
 2件: JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
22 Cholinergic synapse 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
23 Complement and coagulation cascades 💬
 1件: C5 💬 D11838 💬 Vilobelimab 3件: 43, 44, 269 💬
24 Complement and coagulation cascades 💬
 1件: C5AR1 💬 D11093 💬 Avacopan 3件: 43, 44, 222 💬
25 Coronavirus disease - COVID-19 💬
 1件: C5 💬 D11838 💬 Vilobelimab 3件: 43, 44, 269 💬
26 Coronavirus disease - COVID-19 💬
 1件: C5AR1 💬 D11093 💬 Avacopan 3件: 43, 44, 222 💬
27 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
28 Coronavirus disease - COVID-19 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
29 Cytokine-cytokine receptor interaction 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
30 Cytokine-cytokine receptor interaction 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
31 Cytokine-cytokine receptor interaction 💬
 1件: IL5RA 💬 D09874 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
32 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
33 Cytokine-cytokine receptor interaction 💬
 1件: TNFSF13B 💬 D03068 💬 Belimumab 12件: 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300 💬
34 Drug metabolism - other enzymes 💬
 2件: IMPDH1, IMPDH2 💬 D00752 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
35 Drug metabolism - other enzymes 💬
 2件: IMPDH1, IMPDH2 💬 D05094 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
36 Drug metabolism - other enzymes 💬
 2件: IMPDH1, IMPDH2 💬 D05095 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
37 Drug metabolism - other enzymes 💬
 2件: IMPDH1, IMPDH2 💬 D05096 💬 Mycophenolic acid 36件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
38 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
39 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
40 Epstein-Barr virus infection 💬
 3件: JAK1, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
41 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
42 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
43 Fc epsilon RI signaling pathway 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
44 Fc epsilon RI signaling pathway 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
45 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
46 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
47 Graft-versus-host disease 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
48 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
49 Hematopoietic cell lineage 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
50 Hematopoietic cell lineage 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
51 Hematopoietic cell lineage 💬
 1件: IL5RA 💬 D09874 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
52 Hematopoietic cell lineage 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
53 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 D02994 💬 Rituximab 49件:  6 , 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
54 Hepatitis B 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
55 Hepatitis C 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
56 Herpes simplex virus 1 infection 💬
 1件: C5 💬 D11838 💬 Vilobelimab 3件: 43, 44, 269 💬
57 Herpes simplex virus 1 infection 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
58 HIF-1 signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
59 Human cytomegalovirus infection 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
60 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
61 Human papillomavirus infection 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
62 Human T-cell leukemia virus 1 infection 💬
 2件: JAK1, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
63 IL-17 signaling pathway 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
64 IL-17 signaling pathway 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
65 Inflammatory bowel disease 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
66 Inflammatory bowel disease 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
67 Influenza A 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
68 Intestinal immune network for IgA production 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
69 Intestinal immune network for IgA production 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
70 Intestinal immune network for IgA production 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
71 Intestinal immune network for IgA production 💬
 1件: TNFSF13B 💬 D03068 💬 Belimumab 12件: 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300 💬
72 JAK-STAT signaling pathway 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
73 JAK-STAT signaling pathway 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
74 JAK-STAT signaling pathway 💬
 1件: IL5RA 💬 D09874 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
75 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
76 JAK-STAT signaling pathway 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
77 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
78 Kaposi sarcoma-associated herpesvirus infection 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
79 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
80 Lipid and atherosclerosis 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
81 Measles 💬
 3件: JAK1, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
82 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
83 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
84 Metabolic pathways 💬
 2件: IMPDH1, IMPDH2 💬 D00752 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
85 Metabolic pathways 💬
 2件: IMPDH1, IMPDH2 💬 D05094 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
86 Metabolic pathways 💬
 2件: IMPDH1, IMPDH2 💬 D05095 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
87 Metabolic pathways 💬
 2件: IMPDH1, IMPDH2 💬 D05096 💬 Mycophenolic acid 36件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
88 Morphine addiction 💬
 1件: OPRM1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
89 Morphine addiction 💬
 1件: OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
90 Necroptosis 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
91 Neuroactive ligand-receptor interaction 💬
 1件: C5 💬 D11838 💬 Vilobelimab 3件: 43, 44, 269 💬
92 Neuroactive ligand-receptor interaction 💬
 1件: C5AR1 💬 D11093 💬 Avacopan 3件: 43, 44, 222 💬
93 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00472 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
94 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00980 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
95 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00981 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
96 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00982 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
97 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D01239 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
98 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D01998 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
99 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D02156 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
100 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D03301 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
101 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00473 💬 Prednisone 48件:  2 ,  6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬
102 Neuroactive ligand-receptor interaction 💬
 3件: OPRD1, OPRK1, OPRM1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
103 Neuroactive ligand-receptor interaction 💬
 3件: OPRD1, OPRK1, OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
104 Neutrophil extracellular trap formation 💬
 1件: C5 💬 D11838 💬 Vilobelimab 3件: 43, 44, 269 💬
105 Neutrophil extracellular trap formation 💬
 1件: C5AR1 💬 D11093 💬 Avacopan 3件: 43, 44, 222 💬
106 NF-kappa B signaling pathway 💬
 1件: TNFSF13B 💬 D03068 💬 Belimumab 12件: 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300 💬
107 NOD-like receptor signaling pathway 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
108 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
109 Non-small cell lung cancer 💬
 1件: JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
110 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
111 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
112 Osteoclast differentiation 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
113 Pancreatic cancer 💬
 1件: JAK1 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
114 Pathways in cancer 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
115 Pathways in cancer 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
116 Pathways in cancer 💬
 1件: IL5RA 💬 D09874 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
117 Pathways in cancer 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
118 Pathways in cancer 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
119 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
120 Pertussis 💬
 1件: C5 💬 D11838 💬 Vilobelimab 3件: 43, 44, 269 💬
121 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
122 PI3K-Akt signaling pathway 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
123 Primary immunodeficiency 💬
 1件: JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
124 Prion disease 💬
 1件: C5 💬 D11838 💬 Vilobelimab 3件: 43, 44, 269 💬
125 Prolactin signaling pathway 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
126 Purine metabolism 💬
 2件: IMPDH1, IMPDH2 💬 D00752 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
127 Purine metabolism 💬
 2件: IMPDH1, IMPDH2 💬 D05094 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
128 Purine metabolism 💬
 2件: IMPDH1, IMPDH2 💬 D05095 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
129 Purine metabolism 💬
 2件: IMPDH1, IMPDH2 💬 D05096 💬 Mycophenolic acid 36件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
130 Rheumatoid arthritis 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
131 Rheumatoid arthritis 💬
 1件: TNFSF13B 💬 D03068 💬 Belimumab 12件: 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300 💬
132 Signaling pathways regulating pluripotency of stem cells 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
133 Sphingolipid signaling pathway 💬
 1件: OPRD1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
134 Sphingolipid signaling pathway 💬
 1件: OPRD1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
135 Staphylococcus aureus infection 💬
 1件: C5 💬 D11838 💬 Vilobelimab 3件: 43, 44, 269 💬
136 Staphylococcus aureus infection 💬
 1件: C5AR1 💬 D11093 💬 Avacopan 3件: 43, 44, 222 💬
137 Systemic lupus erythematosus 💬
 1件: C5 💬 D11838 💬 Vilobelimab 3件: 43, 44, 269 💬
138 Systemic lupus erythematosus 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
139 T cell receptor signaling pathway 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
140 T cell receptor signaling pathway 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
141 Th1 and Th2 cell differentiation 💬
 1件: IL5 💬 D04923 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
142 Th1 and Th2 cell differentiation 💬
 1件: IL5 💬 D08985 💬 Reslizumab 2件: 44, 98 💬
143 Th1 and Th2 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
144 Th17 cell differentiation 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
145 Th17 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
146 Toll-like receptor signaling pathway 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
147 Toxoplasmosis 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
148 Transcriptional misregulation in cancer 💬
 1件: CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
149 Tuberculosis 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
150 Type I diabetes mellitus 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
151 Viral carcinogenesis 💬
 2件: JAK1, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
152 Viral myocarditis 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
153 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬

先頭へ